Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.48 |
| ▸ | EGFR | P00533 | 9/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060033 | 1.00 | TLR7 (0.48) | TLR7EGFRTLR8KDM4EMEN1 | |
| SCHEMBL843176 | 0.81 | TLR7 (0.46) | TLR7TLR8KDM4ENUDT1 | |
| SCHEMBL4057038 | 0.78 | TLR7 (0.52) | TLR7EGFRTLR8NUDT1 | |
| SCHEMBL5452417 | 0.76 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL4532094 | 0.75 | TLR7 (0.57) | TLR7TLR8MEN1TSHRKMT2A | |
| SCHEMBL29385735 | 0.75 | TLR7 (0.57) | TLR7TLR8MEN1TSHRKMT2A | |
| SCHEMBL17181525 | 0.75 | TLR7 (0.53) | TLR7TLR8TSHRNUDT1 | |
| SCHEMBL4051614 | 0.73 | TLR7 (0.62) | TLR7TLR8NUDT1 | |
| SCHEMBL22158688 | 0.72 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL2059398 | 0.71 | TLR7 (0.46) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784180-A4 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| EP-1784180-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006029115-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | IL2, IL2RA, IL4I1 | TLR7 110/4885EGFR 3500/4885TLR8 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.